Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling

Chen,San-Yuan; Lin,Chun-Hsiang; Lin,Jiun-Tsai; Cheng,Yi-Fang; Chen,Han-Min; Kao,Shao-Hsuan

doi:10.3892/ol.2017.6890

Adenine causes cell cycle arrest and autophagy of chronic myelogenous leukemia K562 cells via AMP-activated protein kinase signaling

Authors:
- San-Yuan Chen
- Chun-Hsiang Lin
- Jiun-Tsai Lin
- Yi-Fang Cheng
- Han-Min Chen
- Shao-Hsuan Kao
View Affiliations

Affiliations: Department of Traditional Chinese Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi 600, Taiwan R.O.C., Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung 402, Taiwan R.O.C., Institute of Applied Science and Engineering, Catholic Fu Jen University, New Taipei 242, Taiwan R.O.C., Energenesis Biomedical Co. Ltd., New Taipei 235, Taiwan R.O.C.
Published online on: September 6, 2017 https://doi.org/10.3892/ol.2017.6890
Pages: 5575-5580

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

AMP-activated protein kinase (AMPK) is known as a pivotal regulator of cellular metabolism. Mounting evidences have demonstrated that AMPK activation exerts tumor suppressive activity on leukemia cells. The present study reported that adenine, an AMPK activator, triggers cell cycle arrest and autophagy of human chronic myelogenous leukemia K562 cells consequently suppressing cell viability. The present findings revealed that adenine treatment (4.0-8.0 mM) significantly inhibited the viability of K562 cells to 69.3±2.5% (24 h) and 53.4±2.1% (48 h) of the control. Flow cytometric analysis revealed that there was a significant accumulation in G2/M phase, but not sub-G1 phase K562 cells following exposure to adenine. Additional investigation demonstrated that adenine treatments significantly increased the number of acidic vesicular organelles and the level of autophagosomal microtubule associated protein 1 light chain 3 α (LC3) marker. By contrast, cleavage of caspase-9, caspase-3 and poly-ADP-ribose polymerase was insignificantly affected in K562 cells following adenine treatment. In K562 cells, adenine was able to markedly promote the phosphorylation of AMPKα and suppress the phosphorylation of mammalian target of rapamycin (mTOR), a downstream target of AMPK. In addition, inhibiting AMPK phosphorylation using dorsomorphin restored mTOR phosphorylation, inhibited the accumulation of LC3 and significantly recovered the suppressed cell viability in response to adenine. Taken together, the present results demonstrated that adenine induced G2/M phase arrest and autophagic cell death, consequently suppressing the viability of K562 cells, which may attribute to the AMPK activation triggered by adenine. These findings provide evidence that adenine may be beneficial to chronic myelogenous leukemia therapy by suppressing excessive cell proliferation.

View Figures

View References

1	Clarkson B, Strife A, Wisniewski D, Lambek CL and Liu C: Chronic myelogenous leukemia as a paradigm of early cancer and possible curative strategies. Leukemia. 17:1211–1262. 2003. View Article : Google Scholar : PubMed/NCBI
2	Traganos F and Darzynkiewicz Z: Lysosomal proton pump activity: Supravital cell staining with acridine orange differentiates leukocyte subpopulations. Methods Cell Biol. 41:185–194. 1994. View Article : Google Scholar : PubMed/NCBI
3	Vakana E, Altman JK, Glaser H, Donato NJ and Platanias LC: Antileukemic effects of AMPK activators on BCR-ABL-expressing cells. Blood. 118:6399–6402. 2011. View Article : Google Scholar : PubMed/NCBI
4	Sujobert P, Poulain L, Paubelle E, Zylbersztejn F, Grenier A, Lambert M, Townsend EC, Brusq JM, Nicodeme E, Decrooqc J, et al: Co-activation of AMPK and mTORC1 induces cytotoxicity in acute myeloid leukemia. Cell Rep. 11:1446–1457. 2015. View Article : Google Scholar : PubMed/NCBI
5	Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ and Jones RJ: Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 83:2038–2044. 1994.PubMed/NCBI
6	Klionsky DJ, Meijer AJ and Codogno P: Autophagy and p70S6 kinase. Autophagy. 1:59–61. 2005. View Article : Google Scholar : PubMed/NCBI
7	Kim I and He YY: Targeting the AMP-activated protein kinase for cancer prevention and therapy. Front Oncol. 3:1752013. View Article : Google Scholar : PubMed/NCBI
8	Vakana E and Platanias LC: AMPK in BCR-ABL expressing leukemias. Regulatory effects and therapeutic implications. Oncotarget. 2:1322–1328. 2011. View Article : Google Scholar : PubMed/NCBI
9	Druker B, Okuda K, Matulonis U, Salgia R, Roberts T and Griffin JD: Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 79:2215–2220. 1992.PubMed/NCBI
10	Gotoh A, Miyazawa K, Ohyashiki K, Tauchi T, Boswell HS, Broxmeyer HE and Toyama K: Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein. Exp Hematol. 23:1153–1159. 1995.PubMed/NCBI
11	Fernandes A, Azevedo MM, Pereira O, Sampaio-Marques B, Paiva A, Correia-Neves M, Castro I and Ludovico P: Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches. Oncotarget. 6:31428–31440. 2015. View Article : Google Scholar : PubMed/NCBI
12	Long YC and Zierath JR: AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest. 116:1776–1783. 2006. View Article : Google Scholar : PubMed/NCBI
13	Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods. 89:271–277. 1986. View Article : Google Scholar : PubMed/NCBI
14	Stankiewicz M, Jonas W, Hadas E, Cabaj W and Douch PG: Supravital staining of eosinophils. Int J Parasitol. 26:445–446. 1996. View Article : Google Scholar : PubMed/NCBI
15	Paglin S, Hollister T, Delohery T, Hackett N, McMahill M, Sphicas E, Domingo D and Yahalom J: A novel response of cancer cells to radiation involves autophagy and formation of acidic vesicles. Cancer Res. 61:439–444. 2001.PubMed/NCBI
16	Hsu CY, Lin CH, Lin JT, Cheng YF, Chen HM and Kao SH: Purine analogue ENERGI-F706 induces apoptosis of 786-O renal carcinoma cells via 5′-adenosine monophosphate-activated protein kinase activation. Mol Med Rep. 12:4566–4571. 2015. View Article : Google Scholar : PubMed/NCBI
17	Sattler M and Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 40 (2 Suppl 2):S4–S10. 2003. View Article : Google Scholar
18	Skorski T, Kanakaraj P, Nieborowska-Skorska M, Ratajczak MZ, Wen SC, Zon G, Gewirtz AM, Perussia B and Calabretta B: Phosphatidylinositol-3 kinase activity is regulated by BCR/ABL and is required for the growth of Philadelphia chromosome-positive cells. Blood. 86:726–736. 1995.PubMed/NCBI
19	Cortez D, Reuther G and Pendergast AM: The Bcr-Abl tyrosine kinase activates mitogenic signaling pathways and stimulates G1-to-S phase transition in hematopoietic cells. Oncogene. 15:2333–2342. 1997. View Article : Google Scholar : PubMed/NCBI
20	Mace ML, Dahl J and Jabbour EJ: Which tyrosine-kinase inhibitor to use first in chronic phase chronic myelogenous leukemia? Expert Opin Pharmacother. 16:999–1007. 2015. View Article : Google Scholar : PubMed/NCBI
21	Adekola K, Popat U and Ciurea SO: An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors. Bone Marrow Transplant. 49:1352–1359. 2014. View Article : Google Scholar : PubMed/NCBI
22	Karnevi E, Said K, Andersson R and Rosendahl AH: Metformin-mediated growth inhibition involves suppression of the IGF-I receptor signalling pathway in human pancreatic cancer cells. BMC Cancer. 13:2352013. View Article : Google Scholar : PubMed/NCBI
23	Zheng QY, Jin FS, Yao C, Zhang T, Zhang GH and Ai X: Ursolic acid-induced AMP-activated protein kinase (AMPK) activation contributes to growth inhibition and apoptosis in human bladder cancer T24 cells. Biochem Biophys Res Commun. 419:741–747. 2012. View Article : Google Scholar : PubMed/NCBI
24	Sauer H, Engel S, Milosevic N, Sharifpanah F and Wartenberg M: Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase. Int J Oncol. 40:501–508. 2012.PubMed/NCBI
25	Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks J, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, et al: MDM2 inhibitor, nutlin 3a, induces p53 dependent autophagy in acute leukemia by AMP kinase activation. PLoS One. 10:e01392542015. View Article : Google Scholar : PubMed/NCBI
26	Mizushima N, Levine B, Cuervo AM and Klionsky DJ: Autophagy fights disease through cellular self-digestion. Nature. 451:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
27	Levine B and Kroemer G: Autophagy in aging, disease and death: The true identity of a cell death impostor. Cell Death Differ. 16:1–2. 2009. View Article : Google Scholar : PubMed/NCBI
28	Settembre C, Fraldi A, Medina DL and Ballabio A: Signals from the lysosome: A control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol. 14:283–296. 2013. View Article : Google Scholar : PubMed/NCBI
29	Gozuacik D and Kimchi A: Autophagy as a cell death and tumor suppressor mechanism. Oncogene. 23:2891–2906. 2004. View Article : Google Scholar : PubMed/NCBI
30	Aredia F and Scovassi AI: Manipulation of autophagy in cancer cells: An innovative strategy to fight drug resistance. Future Med Chem. 5:1009–1021. 2013. View Article : Google Scholar : PubMed/NCBI
31	Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H and Levine B: Induction of autophagy and inhibition of tumorigenesis by beclin 1. Nature. 402:672–676. 1999. View Article : Google Scholar : PubMed/NCBI
32	Yue Z, Jin S, Yang C, Levine AJ and Heintz N: Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci USA. 100:15077–15082. 2003. View Article : Google Scholar : PubMed/NCBI